Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BKM120
PI3K inhibitor BKM120 · 1 trial · 9 indications
Summarized and tabulated by dose level.
| Arm | Type | Description |
|---|---|---|
| Treatment (PI3K inhibitor BKM120, rituximab) | EXPERIMENTAL | Patients receive BKM120 PO daily and rituximab IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with asymptomatic progression may continue treatment for up to 12 months. Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. |
| Name | Type | Description |
|---|---|---|
| PI3K inhibitor BKM120 | DRUG | Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle |
| rituximab | BIOLOGICAL | Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11. |
| Pharmacodynamics | OTHER | Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. |
| Correlative studies | OTHER | Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates. |
Inclusion Criteria: * Patients must have histologically confirmed indolent B-cell NHL or mantle cell lymphoma; acceptable subtypes of indolent B-cell NHL include follicular lymphoma (grades 1, 2, or 3a), marginal zone lymphoma, or lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia; patients...
PI3K inhibitor BKM120 is an investigational small molecule developed by Novartis AG for certain B-cell lymphomas. It has been studied in a Phase 1 trial in adults with relapsed or refractory indolent B-cell lymphoma, including extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. It is not an approved therapy.
PI3K inhibitor BKM120 has been studied in adults with relapsed or refractory indolent B-cell lymphomas, including extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, splenic marginal zone lymphoma, and Waldenström macroglobulinemia. It is investigational and has not been approved for any indication.
PI3K inhibitor BKM120 is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis sponsored the Phase 1 study of BKM120 given with rituximab in patients with relapsed or refractory indolent B-cell lymphoma.
PI3K inhibitor BKM120 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The completed study enrolled 18 participants and was an uncontrolled, non-randomized, open-label study, so it did not include a placebo or comparator arm.
PI3K inhibitor BKM120 has been evaluated in one completed Phase 1 trial, NCT02049541, titled Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma. The trial enrolled 18 adults aged 18 years and older in the United States and combined BKM120 with rituximab.